

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Amended) An immortalized, epithelial tumor cell with metastatic potential which has integrated in its genome or another replicative genetic element an externally introduced immortalizing oncogene which is expressed in said cell, wherein said cell was disseminated from a primary tumor, ~~has the phenotype of the primary tumor~~, and prior to the introduction of said immortalizing oncogene said cell does not divide.

2. Cancelled

3. (Previously Presented) The epithelial tumor cell according to claim 1 which is an autologous tumor cell.

4. (Previously Presented) The epithelial tumor cell according to claim 1 which is a human tumor cell.

5. (Previously Presented) The epithelial tumor cell according to claim 1 which is derived from bone marrow.

6. (Previously Presented) The epithelial tumor cell according to claim 1, wherein said immortalizing oncogene is the DNA encoding the early region of SV40 DNA.

7. (Previously Presented) The epithelial tumor cell according to claim 38, wherein the replication deficiency of said replication deficient SV40 virus is caused by at least one defect in the origin of replication, at least one defect in the antigen coding region or a combination thereof.

8. (Previously Presented) The epithelial tumor cell according to claim 6, wherein said SV40 virus is non-infectious.

9. (Previously Presented) The epithelial tumor cell according to claim 1 which has integrated in its genome at least one additional oncogene.

10. (Original) The epithelial tumor cell according to claim 9, wherein said additional oncogene is ras, mutant WT1, bcl-2, p53mut, myc, HER 2/neu, an HPV16 oncogene, an HPV18 oncogene or E1A.

11. (Previously Presented) The epithelial tumor cell according to claim 1, which further has integrated in its genome or another replicative genetic element at least one externally introduced gene encoding an immunostimulatory factor.

12. (Previously Presented) The epithelial tumor cell according to claim 11, wherein said immunostimulatory factor is B7 or a cytokine.

13-15. Cancelled

16. (Amended) An *in vitro* process for the production of an immortalized, epithelial tumor cell comprising the step of incorporating DNA comprising DNA encoding at least one immortalizing oncogene into a non-immortalized epithelial tumor cell with metastatic potential, wherein said non-immortalized cell was disseminated from a primary tumor, ~~has the phenotype of the primary tumor,~~ and does not divide.

17. (Original) The process according to claim 16, wherein said step of incorporating DNA comprises microinjection or bombardment with DNA-coated microparticles.

18. (Previously Presented) The process according to claim 17, further comprising the step of carrying out a primary expansion of said non-immortalized epithelial tumor cells prior to the microinjection or bombardment step.

19. (Original) The process according to claim 18, wherein said primary expansion comprises the step of culturing tissue or a body fluid comprising non-immortalized epithelial tumor cells in a suitable medium promoting the expansion of said tumor cells.

20. (Previously Presented) The process according to claim 19, wherein said body fluid is bone marrow, blood, ascites or pleural exudate.

21. (Previously Presented) The process according to claim 19, wherein said medium comprises EGF, bFGF, or a combination thereof.

22. (Previously Presented) The process according to claim 19, wherein said culturing step is carried out in ECM-coated tissue flasks, at reduced oxygen concentrations of 5-10%, or in ECM-coated tissue flasks at reduced oxygen concentrations of 5-10%.

23-28. Cancelled

29. (Previously Presented) The epithelial tumor cell according to claim 12, wherein said cytokine is IL-2, IL-4, IL-7, IFN- α or IFN- γ .

30. (Previously Presented) The process according to claim 16, wherein said DNA further comprises DNA encoding at least one gene encoding an immunostimulatory factor.

31. (Previously Presented) The process according to claim 21, wherein EGF is rhEGF and bFGF is rhbFGF.

32. Cancelled

33. (Previously Presented) The composition comprising the epithelial tumor cell according to claim 1, optionally in combination with a pharmaceutically acceptable carrier.

34. (Previously Presented) The composition according to claim 33, wherein said composition comprises a vaccine in combination with a vaccine adjuvant.

35. (Previously Presented) A method of treating a human subject for cancer or prophylaxis of cancer comprising administering a therapeutically effective amount of the composition of claim 33 to a human subject suffering from epithelial cell cancer.

36-37. Cancelled

38. (Previously Presented) The epithelial tumor cell according to claim 6, wherein said early region of SV40 DNA is the large T antigen of a replication deficient SV40 virus.

39. (Previously Presented) The epithelial tumor cell according to claim 1, which is a non-small cell lung cancer cell.

40. (Previously Presented) The epithelial tumor cell according to claim 16, which is a non-small cell lung cancer cell.

41. (New) The method according to claim 35, wherein said immortalized epithelial tumor cell further comprises as integrated in its genome or another replicative genetic element at least one externally introduced gene encoding an immunostimulatory factor.

42. (New) The method according to claim 41, wherein said immunostimulatory factor is B7 or a cytokine.